Genzyme Genetics Announces Expansion of Science and Medical Staff

Date: October 5, 2006

WESTBOROUGH, Mass. – Genzyme Genetics today announced the addition of three new experts to its medical and scientific staffs in its New York City and Los Angeles facilities. Michael Broscius, M.D. and Roberto De La Torre, M.D. join the surgical pathology team in Manhattan, while TuDung Thi Nguyen, M.D., Ph.D., joins the hematopathology team in Los Angeles.

“The impressive credentials that these new pathologists bring to our staff will further enhance the quality of our hematopathology and surgical pathology services,” said Mara Aspinall, president of Genzyme Genetics, a business unit of Genzyme Corporation. “This expansion allows us to optimize our expertise and deliver the most effective and personal service for our clients.”

Prior to joining the surgical pathology team in New York, Michael Broscius, M.D. was the medical director at Pathology Associates of Northeast Pennsylvania. Dr Broscius brings extensive experience in surgical pathology, immunohistochemistry and cytology. He completed his residency training at Hahnemann University Hospital in Philadelphia and his fellowship in oncologic pathology at Memorial Sloan-Kettering Cancer Center in New York City, where he worked closely with Dr. Juan Rosai.

Roberto De La Torre, M.D. joins the surgical pathology team in New York, bringing with him twelve years of experience at Beth Israel Medical Center in New York City as an attending pathologist. His background includes work in the full range of pathology and laboratory medicine services, including surgical pathology, hematopathology, gynecologic and clinical pathology. He also completed his residency training and a two-year fellowship in immunopatholgy at Beth Israel.

Joining the Los Angeles hematopathology team is TuDung Thi Nguyen, M.D., Ph.D. She has recently completed fellowships in hematopathology and molecular pathology at Stanford University Medical Center, where she developed broad experience in the areas of flow cytometry, bone marrow morphology, molecular pathology and immunohistochemistry. TuDung previously completed a fellowship in surgical pathology at Stanford and is board-certified in Anatomic Pathology. She received her M.D. and Ph.D. degrees from the University of Southern California, Keck School of Medicine.

Genzyme employs more than 50 academic and community-trained physicians and scientists with extensive experience in cancer analysis. Using both traditional and cutting edge technologies, the experienced pathologists and hematopathologists review every case and are also available to offer personal consultations, as needed.

About Genzyme Genetics

Genzyme Genetics is a leading, nationwide provider of high-quality, complex testing services for physicians and their patients. With CLIA-certified laboratories and counseling facilities located across the U.S., Genzyme Genetics offers extensive diagnostic testing services, supported by innovative technology and a commitment to quality service and trusted information. Genzyme Genetics is a business unit of Genzyme Corporation.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. This year marks the 25^th anniversary of Genzyme’s founding. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 8,500 employees in locations spanning the globe, and 2005 revenues of $2.7 billion. Genzyme has been selected by FORTUNE as one of the “100 Best Companies to Work for” in the United States.

With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune diseases and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as heart disease and other areas of unmet medical need.